Eric J. Niesor - Concepedia

Author

Eric J. Niesor

Also Known As

E J Niesor, E Niesor, E. J. Niesor, E. NIESOR, E. Niesor, E.J. Niesor, EJ Niesor, Eric J Niesor, Eric J. Bentzen, Eric J. Niesor

106

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)University Hospital of Geneva Université de Montréal Montreal Heart Institute University of Geneva

About

Eric J. Niesor is an author at Roche (Switzerland) specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	938
2	Biochemistry	9	9	451
3	Cell Biology	7	7	450
4	Health Sciences	5	5	235
5	Biomolecular Engineering	1	1	152

Eric J. Niesor

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
A New Selective Peroxisome Proliferator-Activated Receptor γ Antagonist with Antiobesity and Antidiabetic Activity Jennifer Rieusset, Fethi Touri, Liliane Michalik, Molecular Endocrinology	2002	211
Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib Jean‐Claude Tardif, Éric Rhéaume, Louis‐Philippe Lemieux Perreault, Circulation Cardiovascular Genetics	2015	183
A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro Elke Burgermeister, Astride Schnoebelen, Angele Flament, Molecular Endocrinology Novel Partial AgonistInsulin SignalingMolecular PharmacologyMetabolic SyndromeSelective Ppargamma Modulators	2005	154
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport Eric J. Niesor, Christine Magg, Naoto Ogawa, Journal of Lipid Research Lipid PeroxidationDalcetrapib ≤3 µMCellular PharmacologyLipid MovementMolecular Pharmacology	2010	152
The Bile Acid Nuclear Receptor FXR and the Bile Acid Binding Protein IBABP Are Differently Expressed in Colon Cancer Andrea De Gottardi, Fethi Touri, Christoph A. Maurer, Digestive Diseases and Sciences Biliary TractBiliary CancerLiver PhysiologyGastroenterologyColorectal Cancer	2004	135
Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca. Evan A. Stein, Erik S.G. Stroes, George Steiner, The American Journal of Cardiology	2009	134
The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial Kausik K. Ray, Marc Ditmarsch, David Kallend, European Heart Journal	2014	86
The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport Urbain Tchoua, Wilissa D’Souza, Nigora Mukhamedova, Cardiovascular Research	2007	72
Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High-Density Lipoprotein Eric J. Niesor, Gregory G. Schwartz, Anne Perez, Cardiovascular Drugs and Therapy Microrna33 InductionOxysterolAtherosclerosisPhysiologyCholesterol Efflux	2015	67
Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels Roger G. Clerc, Andrea Stauffer, Franziska Weibel, Journal of Hypertension	2010	64

Page 1